These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21098449)

  • 1. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.
    Džavík V; Lavi S; Thorpe K; Yip PM; Plante S; Ing D; Overgaard CB; Osten MD; Lan J; Robbins K; Miner SE; Horlick EM; Cantor WJ
    Circulation; 2010 Dec; 122(23):2411-8. PubMed ID: 21098449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of sPLA2 and endothelial function: a substudy of the SPIDER-PCI trial.
    Lavi S; Thorpe K; Luca MC; Liuni A; Floras J; Horlick EM; Ing D; Osten MD; Overgaard CB; Lan J; Parker JD; Cantor WJ; Džavík V
    Can J Cardiol; 2012; 28(2):215-21. PubMed ID: 22281412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
    Rosenson RS
    Future Cardiol; 2011 Jan; 7(1):11-8. PubMed ID: 21174506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
    Pasceri V; Patti G; Nusca A; Pristipino C; Richichi G; Di Sciascio G;
    Circulation; 2004 Aug; 110(6):674-8. PubMed ID: 15277322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of dynamic cardiac troponin I concentrations and C-reactive protein in the monitoring of myocardial infarction in patients with repeated myocardial infarction].
    Plak M; Orliński L; Łobos M; Ciesielczyk M; Wlazeł RN; Paradowski MT
    Pol Merkur Lekarski; 2010 Jun; 28(168):444-9. PubMed ID: 20642101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study.
    Veselka J; Zemánek D; Hájek P; Malý M; Adlová R; Martinkovicová L; Tesar D
    Am J Cardiol; 2009 Sep; 104(5):630-3. PubMed ID: 19699335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention.
    Pelliccia F; Pasceri V; Marazzi G; Rosano G; Greco C; Gaudio C
    Am Heart J; 2012 Jun; 163(6):1019-23. PubMed ID: 22709755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter by Krijnen et al regarding article, "The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial".
    Krijnen PA; Hack CE; Niessen HW
    Circulation; 2011 Sep; 124(11):e298; author reply e299-300. PubMed ID: 21911792
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
    Rosenson RS; Elliott M; Stasiv Y; Hislop C;
    Eur Heart J; 2011 Apr; 32(8):999-1005. PubMed ID: 21081550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
    Karakas M; Koenig W
    IDrugs; 2009 Sep; 12(9):585-92. PubMed ID: 19697278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of troponin T criteria for periprocedural myocardial infarction in patients with acute coronary syndromes.
    Shugman IM; Diu P; Gohil J; Kadappu KK; Leung M; Lo S; Leung DY; Hopkins AP; Juergens CP; French JK
    Am J Cardiol; 2011 Mar; 107(6):863-70. PubMed ID: 21376928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome.
    Chang SM; Yazbek N; Lakkis NM
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):193-7. PubMed ID: 15170709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
    JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
    Rosenson RS; Hislop C; Elliott M; Stasiv Y; Goulder M; Waters D
    J Am Coll Cardiol; 2010 Sep; 56(14):1079-88. PubMed ID: 20863951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction.
    Briguori C; Colombo A; Airoldi F; Violante A; Focaccio A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Bonizzoni E; Ricciardelli B
    Eur Heart J; 2004 Oct; 25(20):1822-8. PubMed ID: 15474697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
    Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
    Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study.
    Hara H; Nakamura M; Yokouchi I; Kimura K; Nemoto N; Ito S; Ono T; Itaya H; Shiba M; Wada M; Iijima R; Yamamoto M; Yamamoto M; Hara H; Takagi T; Asahara T; Mitsuo K; Kobayashi N; Sugi K
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):357-65. PubMed ID: 19638365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.